Written and maintained by CASRAI Editorial Board
Published
On this page
Research-use information only, not medical advice. This page describes a published measurement instrument. It does not tell anyone how to interpret an individual score or make treatment decisions.
Short answer
SLEDAI, the Systemic Lupus Erythematosus Disease Activity Index, is a weighted clinical index that summarises how active systemic lupus erythematosus (SLE) is across nine organ systems. It was derived in 1992 by the Committee on Prognosis Studies in SLE and later revised as SLEDAI-2K in 2002. Its theoretical maximum is 105.
Definition and scope
The original SLEDAI paper set out to standardise outcome measures in SLE. The authors identified three indices that could describe outcome: disease activity, damage from disease, and health status. SLEDAI is the disease activity index. It is not a damage index and not a health-status questionnaire.
The authors describe it as a validated model of experienced clinicians’ global assessments of disease activity in lupus, representing the consensus of a group of experts in the field of lupus research (Bombardier et al., 1992). It is a tool used by rheumatology researchers and clinicians to record activity in a consistent way, much as other fields use structured scales such as the modified early warning score or CTCAE for their own domains.
How SLEDAI was built and scored
According to the derivation paper’s abstract:
- Twenty-four clinical variables were identified as important for a disease activity index.
- These were used to generate 574 patient profiles, each rated on a 0-10 disease activity scale by 14 rheumatologists.
- A second rating of 10 of the profiles gave scores not significantly different from the first, which the authors took to show that experienced clinicians can reliably make global estimates of disease activity.
- Multiple regression estimated the relative importance of each variable in the physicians’ ratings. Models were fitted on a training set of 75% of the ratings and validated on the remaining 25%.
- The regression coefficients for the organ systems were simplified for easier use in clinical practice, producing a weighted index of nine organ systems.
Organ-system weights in the original SLEDAI
| Weight | Organ systems |
|---|---|
| 8 | Central nervous system; vascular |
| 4 | Renal; musculoskeletal |
| 2 | Serosal; dermal; immunologic |
| 1 | Constitutional; hematologic |
The maximum theoretical score is 105, but the authors note that in practice few patients score above 45. In the testing set, SLEDAI predicted the physicians’ ratings with Pearson correlation coefficients of 0.64 to 0.79.
SLEDAI vs SLEDAI-2K and later variants
SLEDAI-2K, published by Gladman, Ibanez and Urowitz in 2002, revises the original. The key change is that SLEDAI-2K counts persistent active disease in descriptors where the original counted only new or recurrent activity. Persistent activity is now captured for rash, mucous membranes, alopecia and proteinuria.
| Feature | SLEDAI (1992) | SLEDAI-2K (2002) |
|---|---|---|
| Method | Physician-rating profiles, regression, simplified weights | Revision of the original descriptors |
| Persistent activity | Counted new or recurrent only for some descriptors | Also captured for rash, mucous membranes, alopecia, proteinuria |
| Validation reported | 75/25 training and testing split; r = 0.64-0.79 against physician rating | 960-patient cohort, plus a 212-patient subgroup seen at five visits 3-6 months apart (1991-93); r = 0.97 with the original |
| Mortality | Both predicted mortality equally (p = 0.0001) in the 2002 comparison | |
Later published variants
The same research group has since published further work built on SLEDAI-2K. These titles are listed so readers can find the primary literature; consult each paper for what it reports.
- “SLEDAI-2K for a 30-day window” (Lupus, 2010; PMID 19910390)
- “SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation” (Lupus, 2011; PMID 21233149)
- “SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years” (Lupus, 2012; PMID 22800940)
- “SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement” (Journal of Rheumatology, 2015; PMID 26077403)
- “A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index” (Rheumatology, 2018; PMID 29688532)
Where it matters for labs and clinics
Because the index was designed to standardise outcome measures, it gives studies and clinics a common language for SLE activity. A study that reports activity needs to say which version it used, since the original and SLEDAI-2K treat persistent activity differently, and the variant titles above show that observation windows also differ (10 days and 30 days appear in published titles). Comparing scores across papers is only meaningful when the version and window match.
Common misunderstandings
- “The maximum is 105, so scores are spread across 0-105.” 105 is a theoretical maximum; the derivation paper states few patients exceed 45.
- “SLEDAI measures damage.” It measures disease activity. Damage and health status were separate outcome domains in the same standardisation effort.
- “SLEDAI and SLEDAI-2K are interchangeable.” They correlate very highly (r = 0.97 in the 2002 validation), but they are different instruments, and SLEDAI-2K counts persistent activity for several descriptors.
- “A score is a diagnosis or treatment instruction.” It is a research and clinical summary of activity; interpretation belongs with a treating clinician.
FAQ
What does SLEDAI stand for?
Systemic Lupus Erythematosus Disease Activity Index.
Who developed SLEDAI?
Bombardier, Gladman, Urowitz, Caron and Chang, for the Committee on Prognosis Studies in SLE, published in Arthritis and Rheumatism in 1992.
What is the highest possible SLEDAI score?
105 in theory; in practice few patients score above 45, according to the original paper.
What is SLEDAI-2K?
A 2002 revision that also counts persistent activity for rash, mucous membranes, alopecia and proteinuria.
Sources
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH; Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630-640. PubMed 1599520 (read 2026-11-07).
- Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002. PubMed 11838846 (read 2026-11-07).
- Variant papers listed above, identified by PubMed ID (titles checked 2026-11-07).







